» Articles » PMID: 26782170

Exome-wide Single-base Substitutions in Tissues and Derived Cell Lines of the Constitutive Fhit Knockout Mouse

Overview
Journal Cancer Sci
Specialty Oncology
Date 2016 Jan 20
PMID 26782170
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Loss of expression of Fhit, a tumor suppressor and genome caretaker, occurs in preneoplastic lesions during development of many human cancers. Furthermore, Fhit-deficient mouse models are exquisitely susceptible to carcinogen induction of cancers of the lung and forestomach. Due to absence of Fhit genome caretaker function, cultured cells and tissues of the constitutive Fhit knockout strain develop chromosome aneuploidy and allele copy number gains and losses and we hypothesized that Fhit-deficient cells would also develop point mutations. On analysis of whole exome sequences of Fhit-deficient tissues and cultured cells, we found 300 to >1000 single-base substitutions associated with Fhit loss in the 2% of the genome included in exomes, relative to the C57Bl6 reference genome. The mutation signature is characterized by increased C>T and T>C mutations, similar to the "age at diagnosis" signature identified in human cancers. The Fhit-deficiency mutation signature also resembles a C>T and T>C mutation signature reported for human papillary kidney cancers and a similar signature recently reported for esophageal and bladder cancers, cancers that are frequently Fhit deficient. The increase in T>C mutations in -/- exomes may be due to dNTP imbalance, particularly in thymidine triphosphate, resulting from decreased expression of thymidine kinase 1 in Fhit-deficient cells. Fhit-deficient kidney cells that survived in vitro dimethylbenz(a)anthracene treatment additionally showed increased T>A mutations, a signature generated by treatment with this carcinogen, suggesting that these T>A transversions may be evidence of carcinogen-induced preneoplastic changes.

Citing Articles

Integrated analysis of gene alterations in cancer.

Simon-Carrasco L, Pietrini E, Lopez-Contreras A Cell Cycle. 2024; 23(1):92-113.

PMID: 38234243 PMC: 11005815. DOI: 10.1080/15384101.2024.2304509.


Potential Role of the Fragile Histidine Triad in Cancer Evo-Dev.

Niu Z, Jiang D, Shen J, Liu W, Tan X, Cao G Cancers (Basel). 2023; 15(4).

PMID: 36831487 PMC: 9954361. DOI: 10.3390/cancers15041144.


Upregulation of miR-130b Contributes to Risk of Poor Prognosis and Racial Disparity in African-American Prostate Cancer.

Hashimoto Y, Shiina M, Dasgupta P, Kulkarni P, Kato T, Wong R Cancer Prev Res (Phila). 2019; 12(9):585-598.

PMID: 31266828 PMC: 7327781. DOI: 10.1158/1940-6207.CAPR-18-0509.


Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms.

Mafficini A, Scarpa A Endocr Rev. 2019; 40(2):506-536.

PMID: 30657883 PMC: 6534496. DOI: 10.1210/er.2018-00160.


FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.

Dannewitz Prosseda S, Tian X, Kuramoto K, Boehm M, Sudheendra D, Miyagawa K Am J Respir Crit Care Med. 2018; 199(1):83-98.

PMID: 30107138 PMC: 6353016. DOI: 10.1164/rccm.201712-2553OC.


References
1.
Waters L, Minesinger B, Wiltrout M, DSouza S, Woodruff R, Walker G . Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance. Microbiol Mol Biol Rev. 2009; 73(1):134-54. PMC: 2650891. DOI: 10.1128/MMBR.00034-08. View

2.
DiGiovanni J, Sawyer T, Fisher E . Correlation between formation of a specific hydrocarbon-deoxyribonucleoside adduct and tumor-initiating activity of 7,12-dimethylbenz(a)anthracene and its 9- and 10-monofluoroderivatives in mice. Cancer Res. 1986; 46(9):4336-41. View

3.
Francis J, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J . Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours. J Pathol. 2015; 236(2):186-200. DOI: 10.1002/path.4517. View

4.
Saldivar J, Miuma S, Bene J, Hosseini S, Shibata H, Sun J . Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet. 2012; 8(11):e1003077. PMC: 3510054. DOI: 10.1371/journal.pgen.1003077. View

5.
Kim J, Akbani R, Creighton C, Lerner S, Weinstein J, Getz G . Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res. 2015; 21(20):4514-24. PMC: 4610178. DOI: 10.1158/1078-0432.CCR-14-1215. View